# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Ashwani Verma downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Buy to Neutral and lowers the price target ...
RBC Capital analyst Brian Abrahams reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Outperform and maintains $103 pr...
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...
Mizuho analyst Graig Suvannavejh maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target fro...
Canaccord Genuity analyst Sumant Kulkarni maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price t...
Needham analyst Ami Fadia maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $90 t...
Intra-Cellular Therapies reports positive topline results for Study 502 on lumateperone 42 mg as adjunctive therapy for major d...
ITCI: 13% | Intra-Cellular Therapies shares are trading higher after the company announced topline results from its second Phas...